Get the Stockscreener App
1.08
1.82%
-0.02
After Hours:
1.08
Conduit Pharmaceuticals Inc stock is traded at $1.08, with a volume of 740.25K.
It is down -1.82% in the last 24 hours and down -40.66% over the past month.
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.
See More
Previous Close:
$1.10
Open:
$1.11
24h Volume:
740.25K
Relative Volume:
0.23
Market Cap:
$5.08M
Revenue:
-
Net Income/Loss:
$-4.21M
P/E Ratio:
-19.71
EPS:
-0.0548
Net Cash Flow:
-
1W Performance:
-6.90%
1M Performance:
-40.66%
6M Performance:
-91.69%
1Y Performance:
-99.61%
1-Day Range:
$1.04
$1.1183
1-Week Range:
$0.98
$1.16
52-Week Range:
$0.98
$392.00
Conduit Pharmaceuticals Inc Stock (CDT) Company Profile
Name
Conduit Pharmaceuticals Inc
Sector
Industry
Phone
(646) 491 9132
Address
4851 TAMIAMI TRAIL NORTH, NAPLES
Compare CDT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CDT
Conduit Pharmaceuticals Inc
|
1.08 | 5.08M | 0 | -4.21M | 0 | -0.0548 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.01 | 128.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
744.83 | 81.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
571.00 | 34.69B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
233.07 | 30.17B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
242.66 | 26.02B | 3.32B | -860.46M | -1.04B | -8.32 |
Conduit Pharmaceuticals Inc Stock (CDT) Latest News
Is Conduit Pharmaceuticals Inc. (CDT) the Best Micro Cap Stock to Buy Now? - Insider Monkey
Conduit Pharmaceuticals Gets Nasdaq Extension, Plans Capital Market Transfer -March 06, 2025 at 10:42 am EST - Marketscreener.com
Conduit Pharmaceuticals Provides Update on Nasdaq Stock Market Hearing Panel - The Manila Times
Conduit Pharmaceuticals secures Nasdaq extension - Investing.com
Conduit Pharmaceuticals Secures Extension for Nasdaq Compliance Following Bid Price Regaining - Nasdaq
Conduit Pharmaceuticals secures Nasdaq extension By Investing.com - Investing.com Australia
Conduit Pharmaceuticals Inc (NASDAQ: CDT) Is Down -83.09% So Far This Year: What Will Happen Next? - Stocks Register
Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Short Interest Update - Defense World
Taking a look at what insiders are doing to gauge the Conduit Pharmaceuticals Inc (CDT)’s direction - Knox Daily
Conduit Pharmaceuticals Advances Phase II AI Collaboration With Sarborg To Enhance Drug Development - Nasdaq
Conduit Progresses Phase II of its AI Initiative with Sarborg - The Manila Times
How Conduit's New AI System Could Revolutionize Drug Development Decision-Making - StockTitan
Conduit Pharmaceuticals acts to regain Nasdaq compliance By Investing.com - Investing.com South Africa
Conduit Pharmaceuticals acts to regain Nasdaq compliance - Investing.com India
Conduit Pharmaceuticals Files For Offering Of Up To $17.8 Million Of Shares Of Common StockSEC Filing - Marketscreener.com
Understanding the Risks of Investing in Conduit Pharmaceuticals Inc (CDT) - Knox Daily
Conduit Pharmaceuticals to execute 1-for-100 reverse stock split - MSN
Conduit Pharmaceuticals enacts reverse stock split to meet Nasdaq standards - MSN
Conduit Pharmaceuticals, Charles River Laboratories Partner to Evaluate Potential Lupus Treatment - Marketscreener.com
Conduit Pharmaceuticals Partners with Charles River in Clinically Relevant Systemic Lupus Erythematosus Model - The Manila Times
Major Lupus Breakthrough? Conduit Teams Up with Charles River for Game-Changing Treatment Study - StockTitan
Weekly TechBio News 🤹 - substack.com
Conduit Pharmaceuticals announces debt repayment and partial conversion of senior secured note - MSN
Small Cap Stocks To Watch NowFebruary 09th - MarketBeat
Promising Small Cap Stocks To Keep An Eye OnFebruary 07th - MarketBeat
Conduit Pharmaceuticals settles debt, converts senior note - MSN
Conduit Pharmaceuticals Announces Debt Repayment and Partial Conversion of Senior Secured Note - The Manila Times
Conduit Pharmaceuticals settles debt, converts senior note By Investing.com - Investing.com Australia
What is Conduit Pharmaceuticals Inc (CDT) Stock Return on Shareholders’ Capital? - SETE News
Conduit, MGO Global, and Cyclo Therapeutics: Penny Stocks to Watch This Week - PUNE.NEWS
3 Penny Stocks to Watch Now, 2/11/25 - TipRanks
Conduit Pharmaceuticals Inc [CDT] is -58.45% lower this YTD. Is it still time to buy? - The DBT News
CDT’s price-to-cash ratio: Is it a good investment at the moment? - US Post News
Biotech Alert: Searches spiking for these stocks today - TipRanks
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Revolutionizing AI Investment: Why Conduit Pharmaceuticals is a Stock to Watch! - Jomfruland.net
Conduit Pharmaceuticals Inc. (CDT) Advances AI-Driven Drug Development to Phase II - Insider Monkey
Conduit Pharmaceuticals (NASDAQ:CDT) Stock Quotes, Forecast and News Summary - Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Dow Dips 400 Points; US Adds Fewer Than Expected Jobs - Benzinga
CDT Stock Price and Chart — NASDAQ:CDT - TradingView
Stock market news: Conduit Pharmaceuticals +103.87%, Doximity +37.47% among top gainers as corporate earnings surpass investor estimates - Business Upturn
Stock market today: Conduit Pharmaceuticals +83.87%, Doximity +31.02% among top gainers as more companies release their quarterly earnings - Business Upturn
Stock Price Rise As Conduit (CDT) Marks Progress In Strategic Alliance - Stocks Telegraph
Conduit Pharmaceuticals Transitions to Phase II of Sarborg Collaboration to Support AI-Driven Drug Development - The Manila Times
Conduit's AI-Powered Drug Development Takes Major Leap: Real-Time Trial Dashboard Unveiled - StockTitan
Conduit Pharmaceuticals Inc (CDT) requires closer examination - US Post News
Conduit Pharmaceuticals files to sell 5.9M shares of common stock for holders - MSN
Analysts review Conduit Pharmaceuticals Inc’s rating - Knox Daily
Closing Bell Recap: Conduit Pharmaceuticals Inc (CDT) Ends at 1.80, Reflecting a -18.18 Downturn - The Dwinnex
Conduit Pharmaceuticals Inc Stock (CDT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
8.97%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):